Navigation Links
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Date:9/18/2007

LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications for these drugs and fueling continued rapid market growth. In addition to the seven marketed ErbB-pathway inhibitors, more than 50 novel agents targeting this pathway are in development.

"The ErbB Pathway in Cancer" is a series of comprehensive reports published in Future Oncology, New Medicine's premiere newsletter. Future Oncology provides analysis of critical issues in global cancer R&D, clinical practices, markets, and business and company developments. The series covers every aspect of the EGFr/HEr2 inhibitor marketplace, including:

-- Markets (USA and ROW) of approved drugs and forecasts

-- Treatment costs in the USA and ROW

-- Detailed ErbB pathway analyses

-- Associations of ErbB expression and mutations with specific indications

-- EGFr/HEr2-based diagnostic/theragnostic technologies and products

-- Detailed profiles of currently approved drugs

-- Comprehensive reviews of current use of approved drugs by indication

-- Comprehensive reviews of new indications of approved drugs

-- Protocols and interim and final results from clinical trials combining

approved ErbB pathway inhibitors with novel agents.

-- Detailed profiles of over 50 agents in development targeting the ErbB

pathway, including protocols and interim and final results from

hundreds of trials

This series, published in 5 parts, is available for purchase in electronic PDF or hard copy format.


'/>"/>
SOURCE New Medicine
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
4. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
5. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
10. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
11. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- Aprima Medical Software, a leading provider of innovative ... revenue cycle management (RCM) solutions for medical practices, ... Healthcare Data Solutions (HDS) of Coral Cables, FL. ... full support for HDS,s customers, which include approximately ... states. Financial terms were not disclosed. ...
(Date:1/18/2017)... JOSE, Calif. , Jan. 18, 2017  Adaptive Sound ... announced today a new partnership with Hyatt Place Nashville/Downtown ... by providing ASTI LectroFan sleep therapy machines in over ... one of the most important parts of having a ... , general manager of Hyatt Place Nashville/Downtown. "We,re pleased ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Type and by Application: Global Opportunity Analysis and Industry Forecast, 2014 - 2022," ... expected to reach $1,127 million by 2022, growing at a CAGR of 8.26% ... share, in terms of revenue. Continue Reading ... ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 2017 , ... The VA Maryland Health Care System and ... project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, PhD, an ... disease without compromising normal immune function that often occurs during autoimmune diseases. Ultimately ...
(Date:1/18/2017)... Cranbury, NJ (PRWEB) , ... ... ... Times®, the specialty pharmacy industry‚Äôs leading journal and most-read publication among specialty ... Vanderbilt University Medical Center through its Strategic Alliance Partnership (SAP) program, announced ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor ... Smile Train, an international charity that provides free surgery to poor children suffering from ... in the past I have run to support the efforts of the American Heart ...
(Date:1/18/2017)... , ... January 18, 2017 , ... The Portee Insurance ... families and business owners in central Maryland and the DC region, is inaugurating a ... kills 787,000 people nationally every year, making it the #1 killer in America. However, ...
(Date:1/18/2017)... ... , ... At Hallmark Nameplate, their commitment to quality is what sets them ... 13485. This certification is another way they are making constant strides to provide all ... need. , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate and ...
Breaking Medicine News(10 mins):